Bayer, ArcherDX to Develop NGS-Based Companion Diagnostic for Vitrakvi
14 Maio 2020 - 9:00AM
Dow Jones News
By Mauro Orru
Bayer AG said Thursday that it would develop a next-generation
sequencing-based companion diagnostic for Vitrakvi along with
Colorado-based biotechnology company ArcherDX.
The German pharmaceutical and chemical company didn't disclose
financial details, but said its partnership with ArcherDX is aimed
at expanding patient access to genomic testing.
Next-generation sequencing-based companion diagnostic testing
seeks to release molecular information from patients' tumor genomes
to subsequently guide treatment decisions for cancer therapies,
Bayer said.
Write to Mauro Orru at mauro.orru@wsj.com; @MauroOrru94
(END) Dow Jones Newswires
May 14, 2020 07:45 ET (11:45 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Bayer (TG:BAYN)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Bayer (TG:BAYN)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024